A million-person study points to repeated heat injury in the oesophagus.A federal judge on Tuesday said more than 20 defendants including 3M, DuPont, and Honeywell must face claims by Connecticut firefighters who said their protective gear was contaminated by toxic "forever chemicals" that increased their risk of cancer.
Opposing teams of attorneys spent hours on Monday battling over a proposed $7.25 billion settlement of the U.S. Roundup cancer litigation that, if approved, would allow Bayer to keep selling its controversial glyphosate weed killers while providing roughly $10,000 to $165,000 for individuals suffering from cancer they blame on Roundup use.
UCLA scientists engineered ready-made T cells from cord blood stem cells that can hunt solid tumors even when cancer cells hide their main target. T cell receptor therapy, commonly called TCR therapy, is a form of cancer treatment that genetically modifies immune cells known as T cells so they can recognize and attack cancer more [...]
The myriad horrors of the US healthcare system have spawned generations of medical tourism from the wealthiest country on Earth to the periphery: Cuba, Mexico, Costa Rica, Canada, Turkey, and Thailand, to name just a few.
Now, Shanghai is quickly rising as one of the top destinations for cancer patients, as China’s biotech sector has spun an experimental treatment developed in the US into a standalone industry.
New reporting by the Wall Street Journal took a look at this fast-growth industry, centered around chimeric antigen receptor T-cell therapy, or CAR-T for short.
CAR-T is essentially a personalized form of immunotherapy, in which a patient’s own white blood cells are engineered to identify and attack specific proteins found in cancer cells. Though the process was first developed by US biotech giants, their inability — or unwillingness — to lower the cost and increase supply of the treatment has led to shortages throughout the country.
That’s where China comes in. As director of the CAR-T program at the University of Texas MD Anderson Cancer Center in Houston Sairah Ahmed told the WSJ, this therapy can cost around $150,000 to $230,000 in China — still a life-altering bill, but a sizeable discount compared to an insurmountable $550,000 to $850,000 in the US.
This, Ahmed says, is why she advises some patients to seek out treatment in the People’s Republic.
“China has basically done to CAR-T cell therapy the same thing that it’s done to other industries, which is, they’ve industrialized it,” Ahmed explained.
China’s CAR-T services aren’t just cheaper, either. They’re also faster, and come with a host of complimentary after-care treatments, the WSJ notes. As MD Anderson Cancer Center’s explainer on CAR-T therapy advises, the process of extracting and bio-engineering a patient’s cells to fight cancer can take over three weeks in the US. Compare that to China, where the WSJ reports labs near Shanghai can “crank out” the therapy in just a matter of days.
An important caveat here is that CAR-T cell therapy isn’t a catch-all for every type of cancer, and it’s typically only administered after other treatments have failed. It’s not exactly a walk in the park, either, requiring months of recovery and check-ups from a range of physical, neurological, and psychological health specialists. Still, if you had to go through with it, your first step should clearly be pricing out some flights to China.
More on healthcare: Bougie Health Startups Offering Full-Body Diagnostic Scans for Rich People While the Rest of Us Suffer a Crumbling Healthcare System
The post America’s Health Care System Is So Screwed That Patients Are Flying to China for Cancer Treatment appeared first on Futurism.
Artificial intelligence (AI) algorithms that hunt for cancer may do a better job when they approach the analysis as if they were a human pathologist, a new study suggests.
Many AI systems analyze preselected regions of a tissue sample, or they split a whole pathology slide into patches of a fixed size. By contrast, a pathologist searches more dynamically, panning across the tissue, zooming in and out, and pausing over areas that raise red flags. A whole slide can contain billions of pixels, while the evidence of cancer may occupy only a tiny patch.
Study co-author Zhi Huang, an assistant professor of pathology and laboratory medicine at the University of Pennsylvania, compared the process to a search-and-rescue helicopter. "You don't start by inspecting one square meter of ground," Huang told Live Science. You scan the landscape first and then swoop in for a closer look.
In the new study, published in July in the journal Nature, Huang and colleagues demonstrated that cancer-detecting AI might work better when it takes this humanized approach.
AI algorithms called vision language models (VLMs) struggle with the first step that Huang described — that initial, cursory scan. That's in part because many pathology AI systems learn from what pathologists leave behind at the end of that search: a labeled image pointing out where the cancer is or an official diagnosis.
Instead, the researchers trained their new AI on pathologists' search behavior. They called this approach to training "Pathology-CoT," short for "chain of thought." It turns observable actions, including where pathologists move around and zoom in on an image, into training data.
To collect the data, the team created a tool that recorded how pathologists moved around a slide and changed magnification. The raw logs, gathered from eight pathologists, were messy, as a given pathologist might drift across a slide, overshoot their intended region of focus or fiddle with magnification to adjust it to their liking.
To clean up the data, the researchers filtered out those incidental movements, focusing on moments that appeared to represent deliberate attention, such as lingering over one view or making a sustained pan. Then, they compared those regions with eye-tracking data to check that the software was capturing where pathologists were actually looking.
For each region a pathologist inspected, the VLM also drafted a short rationale explaining why the region was worth examining and what features were visible; human pathologists could then accept, edit, or reject the rationale, creating additional training data for the AI. In one example, the AI flagged a portion of a slide as potentially metastatic and suggested zooming in to look for atypical cells. Other inspected regions were flagged as healthy tissue.
Ultimately, the researchers used this training method to build a new tool called Pathology-o3. It scans a slide at low resolution, uses a model trained on pathologists' behavior to choose regions worth a closer look, then sends higher-resolution views of those regions to a VLM for analysis.
Huang said the goal of the new study was not to show that Pathology-o3 worked better than specialized AI models that are specifically built to detect specific types of cancer; those models are often trained disease by disease. Rather, the researchers wanted to see whether their new training approach could help a general-purpose AI navigate a pathology slide more effectively.
They compared Pathology-o3 to other general-use AI systems, such as OpenAI's o3, and asked the algorithms to examine slides containing lymph node tissue. These slides were collected from colorectal cancer cases and some contained metastatic cancer, which human pathologists had already labeled.
The algorithm correctly identified slides that were positive for cancer 100% of the time. However, of the slides it identified as positive, 15.5% were actually negative. By comparison, OpenAI o3 correctly identified slides that were positive for cancer 87.5% of the time. Of the slides it identified as positive, 53.3% were actually negative.
The researchers designed Pathology-o3 to err on the side of flagging something for another look, rather than potentially missing cancer. That might help to explain the rate of false positives, Huang said.
Whether that rate of false alarms is acceptable depends on how Pathology-o3 is used, said Mohammad Asadi, a data scientist at Stanford University who was not involved in the research. It's not precise enough for the AI to diagnose patients on its own, but it could still be useful for a system to point a human toward regions of a slide that are worth double-checking. It may be an advantage that the approach shows the pathologist a specific region to inspect rather than declaring an entire slide suspicious, he said.
The researchers tried repeating the test on an independent dataset that the algorithms hadn't seen before to see how well it worked on unfamiliar slides. Pathology-o3 correctly identified slides that were positive for cancer 97.6% of the time. Of the slides it identified as positive, 37.1% were actually negative. The finding is an example of how AI performance can change when the data source changes, even when the medical task stays the same.
Asadi explained this result suggests the system can still work with slides from a different source. But that result does not yet show that using this tool would make pathologists more accurate or efficient in practice.
The researchers applied their training approach to several existing VLMs, finding that the models' performance consistently improved after the training. That suggests that the navigation data from pathologists was useful across settings, Asadi said.
For Huang, that is the most important result. "The takeaway isn't our system," he said. "It's that the missing ingredient has been sitting in hospitals this whole time."
The study did not compare Pathology-o3 directly with human pathologists, but the researchers said that wasn't their aim.
"The right question isn't whether it beats a pathologist," Huang said. "It's whether a pathologist working with it catches more [cancer cases] and works faster." The current study did not address the latter question, either, but the team's next experiment is designed to test pathologists on the same cases with and without Pathology-o3, measuring what they catch and how long they take to do so.
The system's most plausible use is as a prescreening tool, Asadi said, but he stressed that the research has not yet shown that doctors who use it become faster or more accurate. Asadi wants an even tougher test: trials conducted across multiple hospitals that measure not just accuracy and speed but also pathologists' workloads. He wants the trails to assess the burden of false alarms from the AI algorithms and whether doctors recognize when the AI is wrong.
Importantly, cancer diagnoses can require information from multiple slides, stains and a patient's medical history, while the current system just reads one slide at a time. "I wouldn't claim it should diagnose on its own," Huang said.
This article is for informational purposes only and is not meant to offer medical advice.
A mammogram does more than search for suspicious lumps. It can also show whether a woman’s breasts contain a large amount of dense tissue, a feature that has long been associated with a higher chance of developing breast cancer. For many years, breast density was especially important because it could hide small tumors on mammograms. […]
The post Dense Breasts May Create a Hidden Cancer-Friendly Environment appeared first on Knowridge Science Report.
For more than four decades, pathologists have glimpsed something unsettling under the microscope in the earliest stages of certain cancers: cells with nuclei far larger than they should be, swollen and distorted, lurking in tissue that otherwise appears on the verge of catastrophe. These so-called giant-nucleus cells, or karyomegalic cells, were first spotted in the 1980s in animal experiments involving iron-induced oxidative stress, yet their biological identity and their role in the genesis of cancer remained stubbornly obscure. Now, a team of researchers in Japan has provided the most detailed portrait of these cells to date, and their findings suggest that the enormous nuclei may be far more than a curiosity—they could be the founding population of early cancer, visible before any tumor exists, and potentially useful as a predictor of patient outcomes.
The study, led by Shinya Toyokuni, professor emeritus at Nagoya University Graduate School of Medicine, together with assistant professor Yingyi Kong and colleagues, was published in Redox Biology. The work addresses a deceptively simple question: when iron overload kills most cells in a tissue through oxidative damage, who survives, and what do the survivors become? Iron is an essential micronutrient, but in excess it is a potent carcinogen. Its chemistry is both the reason we need it and the reason it can harm us. Iron catalyzes the formation of hydroxyl radicals from hydrogen peroxide through the Fenton reaction, and these radicals shred DNA, oxidize lipids, and damage proteins. When the damage is severe enough, a form of programmed cell death called ferroptosis is triggered—an iron-dependent demise characterized by lipid peroxidation cascades that rupture the cell membrane. Ferroptosis has become one of the hottest topics in cancer biology precisely because it links iron metabolism, oxidative stress, and cell fate in a single mechanism.
Toyokuni’s team reasoned that if ferroptosis sweeps through iron-damaged tissue, the cells that escape it must be exceptional in some way, and those exceptions might be the seed of malignancy. To find out, they turned to a well-established animal model in which ferric nitrilotriacetate, a carcinogenic iron compound, is injected into rats, delivering a bolus of iron to the kidneys. The compound accumulates in the proximal tubules, where it catalyzes oxidative damage and, over months, produces renal cell carcinoma. In the experiments, the researchers collected kidney tissue before the injection and again one and three weeks afterward. Crucially, they also included a second experimental group: rats carrying a single mutated copy of the BRCA1 gene, the same gene that, when mutated in humans, dramatically raises the risk of breast and ovarian cancers and is associated with renal carcinoma in certain contexts.
The methodological heart of the study lies in its marriage of two technologies. The first is spatial transcriptomics, a technique that maps gene activity across individual cells within a tissue section while preserving the tissue’s original architecture—so researchers can see not only which genes are active but where in the tissue those transcriptional programs are operating. The second is computational nuclear morphometry, which quantifies the size, shape, and density of cell nuclei in the same samples. By overlaying the two datasets, the team could link the physical appearance of each cell—above all, the size of its nucleus—to its underlying transcriptional state. This integration is important because morphological atypia has long been the currency of diagnostic pathology, but connecting that atypia to molecular signatures at single-cell resolution is a recent capability.
What emerged within a week of iron administration was striking. Giant-nucleus cells appeared in the damaged kidneys, and these cells were not simply wounded cells awaiting death. They showed elevated expression of potent oncogenes, including Myc and Met, and they had acquired resistance to ferroptosis—the very cell death pathway that was eliminating their neighbors. In other words, the extreme oxidative environment had functioned as a brutal selective pressure, and the cells best adapted to survive it had activated a program that resembles, in miniature, the hallmark machinery of cancer. The enrichment of Myc, a transcription factor that drives cell growth and proliferation, and Met, a receptor tyrosine kinase involved in invasive growth, paints a picture of cells that are not merely enduring damage but reorganizing themselves around it.
The BRCA1 connection proved equally consequential. BRCA1 is best known as a guardian of the genome, a scaffold for the homologous recombination machinery that repairs double-strand DNA breaks. In the BRCA1-mutant rats, giant-nucleus cells emerged with distinctly different biological profiles from those in wild-type animals. The interpretation the researchers offer is that BRCA1 deficiency cripples DNA repair, so more of the damaged cells that would otherwise die or be repaired instead survive in their injured, genome-compromised state—becoming precancerous giant-nucleus cells. Electron microscopy and cellular respiration measurements reinforced this idea at the subcellular level: cells from BRCA1-mutant rats showed mitochondrial remodeling, with impaired iron handling and compromised respiratory function. Mitochondria, long appreciated as power plants, are also central regulators of ferroptosis and iron metabolism, and their disarray in the mutant animals may be both a consequence of BRCA1 loss and a driver of the abnormal iron biology that feeds karyomegaly.
Using their combined gene-expression and nuclear-shape data, the researchers went further and classified the giant-nucleus cells into six distinct types. One type possessed extremely large nuclei and gene signatures of stress-induced growth arrest—cells that appear to have locked themselves into a senescent-like state, consistent with profiles reported in earlier studies. Another type, found more frequently in BRCA1-mutant kidneys, showed heightened activity of cancer-related genes alongside elongated nuclei, a combination the authors interpret as a potential precancerous state. The taxonomy matters because it reframes giant-nucleus cells from a single enigmatic category into a spectrum, some members of which may be harmless or even protective while others carry genuine malignant potential.
One of the most provocative findings concerns the cells surrounding the giants. Even morphologically normal cells near giant-nucleus cells exhibited gene expression changes that appear to promote survival, suggesting that the karyomegalic cells remodel their local microenvironment in ways that extend beyond their own borders. In BRCA1-mutant kidneys, the team also documented a substantial increase in stromal cells—non-cancerous supportive cells including immune and connective tissue elements—around the damaged regions. The local tissue environment, the tumor niche in the language of modern oncology, was being reshaped long before any tumor could be called a tumor. This raises the possibility that a single conspicuous cell, easily identified by its nucleus under a conventional microscope, could serve as a sentinel for a whole neighborhood of incipient malignancy.
The leap from rat kidneys to human medicine came through two complementary analyses. First, the researchers mined TCGA-KIRC, a large public database of kidney cancer patients, asking whether tumors carrying gene-expression patterns resembling the cancer-prone giant-nucleus cells were associated with different clinical trajectories. They were: patients whose tumors shared the gene patterns of the cancer-prone giant-nucleus cells had shorter survival times, while those with patterns resembling the healthier giant-nucleus cell types had better outcomes. Not all giant-nucleus cells, in other words, are created equal, and the transcriptional fingerprints defined in the rat model appear to carry prognostic weight in human disease. Second, in a small pilot study, the team examined breast tissue from seven individuals with inherited BRCA1 mutations and fifteen without, observing abnormal nuclear features similar to those in the animal model in the mutation carriers. While the sample size is modest, the parallel hints that karyomegaly may be a cross-tissue marker of BRCA1-linked precancerous change.
The broader implications run in two directions. Clinically, the promise is that giant-nucleus cells, being easy to spot under the microscope, could function as early indicators of cancer—visible warnings in tissue that would otherwise be classified as merely damaged or inflamed. The TCGA survival data suggest that their gene-expression signatures might even stratify patients by risk once a tumor has formed. Scientifically, the study offers a concrete mechanism connecting an environmental exposome factor—iron-catalyzed oxidative stress—to a defined, transcriptionally characterized precancerous population, with ferroptosis resistance as the pivot. It also implies testable therapeutic hypotheses: if blocking mitochondrial remodeling or reversing ferroptosis resistance could prevent the persistence of the precancerous cells, early intervention might stop cancer before it starts. Toyokuni and his colleagues are careful to note that long-term studies will be needed to determine how giant-nucleus cells actually progress into tumor cells, whether such interventions can work, and whether nuclear shape combined with gene patterns can be validated as a diagnostic in larger patient cohorts. But the central message is already legible: some of the earliest chapters of cancer may be written in cells that have grown too large to be ignored.
Article Title: Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis.
Article References: Kong, Y., Shiraki, Y., Furuhashi, K., Maruyama, S., Imaoka, T., Enomoto, A., & Toyokuni, S. (2026). Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis. Redox Biology, 95, Article 104293. https://doi.org/10.1016/j.redox.2026.104293
Image Credits: AI Generated
DOI: 10.1016/j.redox.2026.104293
Keywords: giant-nucleus cells, karyomegaly, ferroptosis, BRCA1, iron-catalyzed oxidative stress, spatial transcriptomics, renal carcinogenesis, mitochondrial remodeling, nuclear morphometry, precancerous cells, TCGA-KIRC, Nagoya University
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they need to grow. Weill Cornell Medicine investigators have now traced one possible route of resistance to amino acid metabolism, where a [...]Pre-surgery immunotherapy kept a group of bowel cancer patients cancer-free for nearly three years, while personalized blood tests helped predict treatment response. Patients with a specific form of bowel cancer who received a short course of immunotherapy before surgery, rather than chemotherapy afterward, have remained cancer-free for nearly three years, according to updated findings from [...]In a finding that could reshape the search for new treatments against one of the deadliest gynecologic malignancies, researchers in Shanghai have identified the approved lung cancer drug tepotinib as a potent inhibitor of ovarian cancer growth, acting through an unexpected molecular target known as LY75. The study, published in the Journal of Ovarian Research, combines large-scale computational screening, structural biology, and preclinical testing to make a case for repurposing an existing medicine against a disease that urgently needs new options.
Ovarian cancer remains one of the most lethal cancers affecting women, largely because it is often diagnosed at an advanced stage and because resistance to platinum-based chemotherapy and PARP inhibitors eventually develops in most patients. High-grade serous ovarian cancer, the most common and aggressive subtype, has proven particularly stubborn, and survival rates have improved only marginally over recent decades. Against this backdrop, the idea of finding new uses for drugs that have already passed safety testing in humans, a strategy known as drug repurposing, has gained considerable traction. The new study demonstrates how modern computational tools can accelerate that process dramatically.
The research team, led by Yang Xiao, Wei Xia, and Yanan Song of Pudong Gongli Hospital and the Shanghai University of Medicine and Health Sciences, began by focusing on LY75, also known as CD205 or DEC205, a C-type lectin receptor best known for its role in antigen uptake by dendritic cells. Mining data from The Cancer Genome Atlas and the Human Protein Atlas, the investigators found that LY75 was significantly upregulated in ovarian cancer tissues compared with healthy tissue. More importantly, elevated LY75 expression correlated with shorter progression-free survival, marking the protein as both a potential biomarker of aggressive disease and an attractive therapeutic target.
With the target in hand, the team turned to structure-based virtual screening. Rather than testing thousands of compounds in the laboratory, they used the published crystal structure of the LY75 protein, deposited in the Protein Data Bank under the identifier 8K8H, as a template to computationally dock molecules from the TargetMol compound library. Docking predicts how well a small molecule fits into a binding pocket on a protein, but the researchers went considerably further. They applied MM/GBSA calculations, a method that estimates binding free energy by combining molecular mechanics forces with implicit solvent models, to rescore candidate poses. They also employed protein-ligand interaction fingerprints, or PLIF analysis, to compare the binding patterns of candidates against known interaction motifs, and ran ADMET predictions to filter out compounds likely to fail on absorption, metabolism, or toxicity grounds before any experiment was performed.
From this computational funnel, tepotinib emerged as the leading candidate. Tepotinib is an orally available small molecule approved in several countries for the treatment of non-small cell lung cancer harboring MET exon 14 skipping mutations, where it acts as a MET kinase inhibitor. Its appearance as a strong LY75 binder raised an obvious question: was any anti-cancer effect simply a consequence of MET inhibition? The team anticipated this concern and designed their study around it, measuring c-MET expression in their cell models, examining MET–LY75 co-expression patterns, and running parallel pharmacological controls with capmatinib, another selective MET inhibitor, to disentangle the two mechanisms.
The laboratory experiments delivered striking results. Tepotinib preferentially inhibited ovarian cancer cell lines with high LY75 expression, achieving half-maximal inhibitory concentrations, or IC₅₀ values, of 16.31 micromolar in SKOV3 cells and 18.91 micromolar in OVCAR-8 cells. In contrast, the drug showed markedly weaker activity against HO8910 cells, which express low levels of LY75, a dose-response pattern consistent with LY75 serving as the drug’s relevant target rather than an incidental one. To confirm a direct physical interaction, the researchers turned to surface plasmon resonance, a label-free optical technique that measures real-time binding between molecules immobilized on a sensor surface. The experiments confirmed that tepotinib binds LY75 directly, with a kinetic dissociation constant of 2.52 micromolar and a steady-state K_D of 3.74 micromolar, values indicating a specific and measurable interaction.
Perhaps the most intriguing mechanistic finding concerns what tepotinib does to the LY75 protein once bound. Treatment with the drug induced apoptosis in the sensitive cell lines, suppressed their migratory capacity, a process closely tied to metastatic spread, and downregulated LY75 protein levels. When the team probed how this downregulation occurred, they found that tepotinib accelerated LY75 degradation through a pathway that does not depend on the ubiquitin-proteasome system, the cell’s standard machinery for tagging unwanted proteins for destruction. Cycloheximide chase experiments, which block new protein synthesis and allow the decay rate of existing proteins to be measured, supported this conclusion. The identity of the alternative degradation route remains an open question, but the observation suggests tepotinib may engage lysosomal or autophagic pathways, a hypothesis that will require further work to confirm.
The in vivo evidence proved even more compelling. In mouse xenograft models implanted with SKOV3 ovarian cancer cells, oral administration of tepotinib markedly suppressed tumor growth, achieving a tumor inhibition rate of 79.6 percent. Analysis of the excised tumors showed reduced LY75 expression in the treated animals, consistent with the drug engaging its target in living tissue. All animal procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Health Medical College and conducted in accordance with the ARRIVE guidelines for reporting animal research.
Crucially, the MET controls strengthened rather than weakened the case for LY75 as the operative target. Capmatinib, a structurally distinct MET inhibitor, failed to reproduce the full anti-tumor activity of tepotinib in the ovarian cancer models, and analyses of c-MET expression and MET–LY75 co-expression in patient datasets suggested that MET inhibition alone could not account for the magnitude of benefit observed. The authors therefore conclude that tepotinib’s effect in ovarian cancer reflects a genuine dual pharmacology, with LY75 binding and subsequent LY75 protein downregulation contributing substantially to its activity.
The implications of the study extend in several directions. First, it elevates LY75 from an immunological curiosity to a candidate therapeutic target in ovarian cancer, a protein whose abundance in tumors and association with poor prognosis make it a marker worth tracking clinically. LY75 has already attracted attention in oncology as a target for antibody-drug conjugates, given its presence on the surface of certain tumor cells and its efficient internalization, and the new findings add a small-molecule dimension to that conversation. Second, the work offers a template for computational drug repurposing: crystal-structure-guided docking, energy-based rescoring, interaction fingerprinting, and ADMET filtering followed by rigorous biochemical and in vivo validation. The approach identifies candidates in silico in a fraction of the time and cost of conventional screening campaigns.
Third, and most immediately, the results argue for clinical exploration of tepotinib in ovarian cancer, particularly in patients whose tumors express high levels of LY75. Because the drug is already approved and its safety profile in humans is documented, the path from laboratory finding to clinical trial is potentially shorter than for a de novo compound. The micromolar potencies observed in cell culture are modest by the standards of modern targeted therapy, and patients would likely require careful dosing studies, biomarker-based selection, and possibly drug combinations to translate the xenograft results into human benefit. Questions also remain about whether the ubiquitin-proteasome-independent degradation mechanism operates identically in human tumors and about the precise structural features of the tepotinib–LY75 interaction that could be optimized in next-generation analogs.
The study is not without limitations, as its authors acknowledge. The work relies on cell lines and xenografts rather than patient-derived models, and the correlation between LY75 expression and drug sensitivity, while suggestive, has been established across only a handful of cell lines. Prospective validation in patient-derived xenografts and organoids, ideally stratified by LY75 expression, would sharpen the biomarker hypothesis considerably. Nonetheless, the convergence of computational prediction, biochemical confirmation, mechanistic insight, and animal efficacy data makes this one of the more complete preclinical repurposing cases published for ovarian cancer in recent memory.
For a disease in which the therapeutic arsenal has expanded slowly and resistance is nearly universal, the prospect that a drug already sitting on pharmacy shelves could be redirected against a newly validated molecular target is the kind of story that resonates far beyond the laboratory. If follow-up studies and early-phase trials bear out these findings, tepotinib’s second act may prove more consequential than its first, and LY75 may take its place among the actionable targets of precision oncology.
Article Title: Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening
Article References: Xiao, Y., Han, Y., Kong, W., Cheng, J., Xia, W., & Song, Y. (2026). Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02230-7
Image Credits: AI Generated
DOI: 10.1186/s13048-026-02230-7
Keywords: Ovarian cancer, LY75, Tepotinib, Virtual screening, Drug repurposing, Molecular targeted therapy, Surface plasmon resonance, Tumor biomarkers
Login